Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Medical Research Collaborating Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Am J Cardiol. 2019 Feb 1;123(3):446-453. doi: 10.1016/j.amjcard.2018.10.024. Epub 2018 Nov 6.
Although current guidelines recommend mitral valve repair (MVr) over mitral valve replacement (MVR) for patients with mitral regurgitation (MR), it is unclear if it should be also recommended in elderly patients with limited life expectancy. This study was conducted to compare the results of MVr with those of MVR to determine the optimal treatment option for patients with degenerative MR, particularly according to the patient's age. A literature search of 5 electronic databases was performed. The primary outcome was all-cause mortality. The secondary outcomes included early mortality and freedom from reoperation. A metaregression analysis and subgroup analysis were performed according to the mean age of the study population. Twelve retrospective studies (2,950 and 1,252 patients in the MVr and MVR groups, respectively) were selected. Pooled analyses demonstrated that the risk of all-cause mortality was significantly higher in the MVR group than in the MVr group both in all studies and in studies presenting adjusted results (hazard ratio[95% confidence interval] = 1.57[1.39 to 1.77] and 1.53[1.34 to 1.74], respectively). This benefit was similar across all ages when the metaregression analysis and the subgroup analysis were performed (p = 0.879 and 0.123, respectively). Early mortality and risk of reoperation were also higher in the MVR group than in the MVr group (risk ratio[95% confidence interval] = 4.51[3.12 to 6.51] and hazard ratio[95% confidence interval] = 1.47[1.09 to 1.98], respectively). In conclusion, this study indicates that MVr is beneficial compared with MVR in patients with degenerative MR regardless of patients' age in terms of all-cause mortality.
尽管目前的指南建议对于二尖瓣反流(MR)患者采用二尖瓣修复术(MVr)而非二尖瓣置换术(MVR),但对于预期寿命有限的老年患者,是否也应推荐采用 MVr 还不清楚。本研究旨在比较 MVr 和 MVR 的结果,以确定退行性 MR 患者的最佳治疗选择,特别是根据患者的年龄。对 5 个电子数据库进行了文献检索。主要结局是全因死亡率。次要结局包括早期死亡率和免于再次手术。根据研究人群的平均年龄进行了荟萃回归分析和亚组分析。共纳入 12 项回顾性研究(MVr 组和 MVR 组分别为 2950 例和 1252 例患者)。汇总分析显示,在所有研究和校正结果的研究中,MVR 组的全因死亡率均显著高于 MVr 组(风险比[95%置信区间]分别为 1.57[1.39 至 1.77]和 1.53[1.34 至 1.74])。当进行荟萃回归分析和亚组分析时,这种获益在所有年龄段都是相似的(p 值分别为 0.879 和 0.123)。MVR 组的早期死亡率和再次手术风险也高于 MVr 组(风险比[95%置信区间]分别为 4.51[3.12 至 6.51]和风险比[95%置信区间]分别为 1.47[1.09 至 1.98])。总之,本研究表明,对于退行性 MR 患者,无论患者年龄如何,MVr 均优于 MVR,可降低全因死亡率。